Ligand Pharmaceuticals Inc. (LGND)

187.81
7.20 3.70
NASDAQ : Health Technology
Prev Close 194.99
Open 196.01
Day Low/High 187.14 / 196.56
52 Wk Low/High 107.64 / 195.17
Volume 174.37K
Avg Volume 307.20K
Exchange NASDAQ
Shares Outstanding 21.30M
Market Cap 3.95B
EPS 0.60
P/E Ratio 76.76
Div & Yield N.A. (N.A)

Latest News

Ratings Changes Today

TheStreet Quant Ratings provides fair and objective information to help you make educated investing decisions. We rate over 4,100 stocks daily and provide 5-page PDF reports for each stock. These ratings can change daily and today's changes are reflected in the email below. If you are looking to check-up on the stocks you currently own or are looking for new ideas, you can find our full database of password-protected ratings reports in our proprietary ratings screener: http://www.thestreet.com/k/qr/flat/stock-screener.html Upgrades: AKAM, ALB, DIOD, ECOM, EZPW, FRGI, GWRS, HIBB, HLX, LGND, MTCH, OIIM, PWOD Downgrades: BWINA, BWINB, GBL, ICUI, MOC, RCM, SINA, TPRE Initiations: ARA, FBM, PUMP Read on to get TheStreet Quant Ratings' detailed report:

LGND Crosses Above Average Analyst Target

In recent trading, shares of Ligand Pharmaceuticals Inc have crossed above the average analyst 12-month target price of $160.00, changing hands for $168.99/share. When a stock reaches the target an analyst has set, the analyst logically has two ways to react: downgrade on valuation, or, re-adjust their target price to a higher level.

Ligand Enters Into Agreement With VenBio To Make Worldwide OmniAb® Platform License Accessible To Portfolio Companies

Ligand Enters Into Agreement With VenBio To Make Worldwide OmniAb® Platform License Accessible To Portfolio Companies

Ligand Pharmaceuticals Incorporated (NASDAQ: LGND) announces it has entered into an agreement with venBio Partners, a venture capital group focused on building and funding portfolio companies with potential first- and...

Ligand Licenses Glucagon Receptor Antagonist Program To Roivant Sciences

Ligand Licenses Glucagon Receptor Antagonist Program To Roivant Sciences

Ligand Pharmaceuticals Incorporated (NASDAQ: LGND) today announced the signing of a license agreement granting Roivant Sciences exclusive global rights to develop and commercialize LGD-6972, Ligand's glucagon receptor...

Ligand To Participate In Two Upcoming Investor Conferences

Ligand To Participate In Two Upcoming Investor Conferences

Ligand Pharmaceuticals Incorporated (NASDAQ: LGND) announces that company executives are scheduled to participate in the following upcoming investor conferences: • 30 th Annual ROTH Conference in Dana Point,...

Ratings Changes Today

TheStreet Quant Ratings provides fair and objective information to help you make educated investing decisions. We rate over 4,100 stocks daily and provide 5-page PDF reports for each stock. These ratings can change daily and today's changes are reflected in the email below. If you are looking to check-up on the stocks you currently own or are looking for new ideas, you can find our full database of password-protected ratings reports in our proprietary ratings screener: http://www.thestreet.com/k/qr/flat/stock-screener.html Upgrades: CCRN, CNSL, CWST, GPS, KRA, PSTG, RBA, SEM, SWN, WPX Downgrades: CBPO, CPLA, GBLI, HPT, INXN, LGND, MCC, NRG, PEP, XOXO Initiations: LAUR Read on to get TheStreet Quant Ratings' detailed report:

Ligand Reports Fourth Quarter And Full Year 2017 Financial Results

Ligand Reports Fourth Quarter And Full Year 2017 Financial Results

Ligand Pharmaceuticals Incorporated (NASDAQ: LGND) today reported financial results for the three and 12 months ended December 31, 2017, and provided an operating forecast and program updates.

Ligand To Report Fourth Quarter And Full Year 2017 Results On February 21st

Ligand To Report Fourth Quarter And Full Year 2017 Results On February 21st

Ligand Pharmaceuticals Incorporated (NASDAQ: LGND) announced today plans to report fourth quarter and full year 2017 financial results on February 21, 2018.

Ligand Enters Into Worldwide OmniAb® Platform License Agreement With Ferring Pharmaceuticals

Ligand Enters Into Worldwide OmniAb® Platform License Agreement With Ferring Pharmaceuticals

Ligand Pharmaceuticals Incorporated (NASDAQ: LGND) announces it has entered into a worldwide OmniAb platform license agreement with Ferring Pharmaceuticals.

Ligand Establishes Program To Develop Captisol-Enabled, Next-Generation Contrast Agents For Diagnostic Imaging

Ligand Establishes Program To Develop Captisol-Enabled, Next-Generation Contrast Agents For Diagnostic Imaging

Ligand Pharmaceuticals Incorporated (NASDAQ: LGND) announces initiation of a program to develop contrast agents with reduced renal toxicity.

Ligand Enters Into Worldwide OmniAb® Platform License Agreement With Glenmark Pharmaceuticals

Ligand Enters Into Worldwide OmniAb® Platform License Agreement With Glenmark Pharmaceuticals

Ligand Pharmaceuticals Incorporated (NASDAQ: LGND) announces it has entered a worldwide OmniAb platform license agreement with Glenmark Pharmaceuticals.

Ligand Earns $6 Million As OmniAb Partner Out-Licenses Antibody Projects

Ligand Earns $6 Million As OmniAb Partner Out-Licenses Antibody Projects

Ligand Pharmaceuticals Incorporated (NASDAQ: LGND) announces that its partner HanAll Biopharma successfully out-licensed antibody projects that were discovered by HanAll using Ligand's OmniAb ® antibody discovery...

Ligand Provides Highlights From Today's Analyst Day Event

Ligand Provides Highlights From Today's Analyst Day Event

At an Analyst Day event held today in New York City, Ligand Pharmaceuticals Incorporated (NASDAQ: LGND) reviewed the recent progress of its business, including its revenue growth opportunities, its portfolio of partnered...

Ligand Reports Third Quarter 2017 Financial Results

Ligand Reports Third Quarter 2017 Financial Results

Ligand Pharmaceuticals Incorporated (NASDAQ: LGND) today reported financial results for the three and nine months ended September 30, 2017, and provided an operating forecast and program updates.

Reminder: Ligand To Host Analyst Day On November 14th In New York City

Reminder: Ligand To Host Analyst Day On November 14th In New York City

Ligand Pharmaceuticals Incorporated (NASDAQ: LGND) will host an Analyst Day on Tuesday, November 14, 2017 from 4:00 p.

Ligand To Participate In The Stephens Fall Investment Conference

Ligand To Participate In The Stephens Fall Investment Conference

Ligand Pharmaceuticals Incorporated (NASDAQ: LGND) announces that the company is scheduled to participate in the Stephens Fall Investment Conference in New York City.

Ligand To Report Third Quarter 2017 Results On November 9th

Ligand To Report Third Quarter 2017 Results On November 9th

Ligand Pharmaceuticals Incorporated (NASDAQ: LGND) announced today that it plans to report third quarter 2017 financial results after market close on November 9, 2017 and to provide additional commentary during its Analyst...

Ligand To Host Analyst Day On November 14th In New York City

Ligand To Host Analyst Day On November 14th In New York City

Ligand Pharmaceuticals Incorporated (NASDAQ: LGND) will host an Analyst Day on Tuesday, November 14, 2017 from 4:00 p.

Ligand Announces Top-Line Results From Phase 2 Study Of LGD-6972 In Patients With Type 2 Diabetes

Ligand Announces Top-Line Results From Phase 2 Study Of LGD-6972 In Patients With Type 2 Diabetes

Ligand Pharmaceuticals Incorporated (NASDAQ: LGND) today announced positive top-line results from a Phase 2 clinical study evaluating the efficacy and safety of LGD-6972, as an adjunct to diet and exercise, in subjects...

Ligand To Participate In Two Upcoming Investor Conferences

Ligand To Participate In Two Upcoming Investor Conferences

Ligand Pharmaceuticals Incorporated (NASDAQ: LGND) announces that company executives are scheduled to participate in the following upcoming investor conferences: Citi's 12 th Annual Biotech Conference in...

Ligand Appoints Dr. Nancy Gray To Its Board Of Directors

Ligand Appoints Dr. Nancy Gray To Its Board Of Directors

Ligand Pharmaceuticals Incorporated (NASDAQ: LGND) ("Ligand" or "the Company") announces the appointment of Nancy Ryan Gray, Ph.

Ligand To Receive $2 Million From WuXi Biologics For Licensing Clinical-Stage Anti-PD-1 Antibody Discovered Using The OmniAb® Technology

Ligand To Receive $2 Million From WuXi Biologics For Licensing Clinical-Stage Anti-PD-1 Antibody Discovered Using The OmniAb® Technology

Ligand Pharmaceuticals Incorporated (NASDAQ: LGND) ("Ligand" or "the Company") announces that it will receive a $2 million payment from WuXi Biologics subsequent to their licensing of exclusive rights to the anti-PD-1...

Ratings Changes Today

TheStreet Quant Ratings provides fair and objective information to help you make educated investing decisions. We rate over 4,200 stocks daily and provide 5-page PDF reports for each stock. These ratings can change daily and today's changes are reflected in the email below. If you are looking to check-up on the stocks you currently own or are looking for new ideas, you can find our full database of password-protected ratings reports in our proprietary ratings screener: http://www.thestreet.com/k/qr/flat/stock-screener.html Upgrades: AAV, ARCC, BID, CFG, ENSG, EXEL, GCAP, HAE, HMLP, LGND, MOMO, MTW, PBR, RYI Downgrades: AEUA, ATSG, ATW, LMNX, MOH, MSB, NBEV, PAGP, SAVE, TIS Initiations: MCRB, TWLO Read on to get TheStreet Quant Ratings' detailed report:

Ligand Reports Second Quarter 2017 Financial Results

Ligand Reports Second Quarter 2017 Financial Results

Ligand Pharmaceuticals Incorporated (NASDAQ: LGND) today reported financial results for the three and six months ended June 30, 2017, and provided an operating forecast and program updates.

TheStreet Quant Rating: A- (Buy)